U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday.Following the market opening Tuesday, the Dow traded down 0.04% to 42,286.94 while the NASDAQ rose 0.26% to 19,292.19. The S&P 500 also rose, gaining, 0.04% to 5,938.09.Check This Out: Jim Cramer Recommends Nvidia Over ‘Very Cheap’ Semiconductor StockLeading and Lagging SectorsInformation technology shares jumped by 0.6% on Tuesday.In trading on Tuesday, real estate stocks fell by 1.1%.Top HeadlineDollar Gen ...

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Tuesday.Shares of Rio Tinto Group RIO fell sharply in today's pre-market trading.Jefferies analyst Chris LaFemina downgraded the rating for Rio Tinto from Buy to Hold.Rio Tinto shares dipped 2.1% to $58.36 in the pre-market trading session.Latest Startup Investment Opportunities:Here are some other stocks moving lower in pre-market trading.Bumble Inc. BMBL shares dipped 5.8% to $5.41 in today's pre-market trading. ...

Dollar General Corporation DG will release its first-quarter financial results before the opening bell on Tuesday, June 3.Analysts expect the company to report quarterly earnings at $1.49 per share, down from $1.65 per share in the year-ago period. Dollar General projects quarterly revenue of $10.29 billion, compared to $9.91 billion a year earlier, according to data from Benzinga Pro.The company has beaten analyst revenue estimates for two straight quarters and in five of the last six quarters.Dollar Gener ...

Bank of America Securities analyst Jessica Reif Ehrlich maintained a Buy rating on Warner Bros. Discovery WBD with a price forecast of $14 on Monday.Ehrlich argued, in an analyst report, that recent developments, notably an internal reorganization and an S&P debt downgrade (viewed as an “ironically positive” event), have increased WBD’s strategic flexibility.While acknowledging challenges, the analyst expressed continued belief in WBD’s compelling collection of assets and upcoming catalysts.Also Read: Warne ...

Zai Lab Limited ZLAB and NovoCure Limited NVCR revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting.The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclita ...

Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at week six.Also Read: Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock JumpsThe 108 mg BID, 54 mg BID and 27 mg BID dose gr ...

公司财报与预期 - 公司将于6月3日盘前发布第一季度财报 分析师预计每股收益为71美分 低于去年同期的73美分 [1] - 预计季度营收为5.6575亿美元 高于去年同期的5.0882亿美元 [1] - 第四季度调整后每股收益为1.19美元 符合分析师共识预期 季度销售额为6.671亿美元(同比增长2.8%) 低于分析师预期的6.745亿美元 [2] 股价表现 - 公司股价上周五下跌0.3% 收于111.45美元 [2] 分析师评级与目标价调整 - Keybanc分析师Bradley Thomas维持超配评级 目标价从125美元上调至135美元 [9] - JP Morgan分析师Matthew Boss维持超配评级 目标价从135美元上调至137美元 [9] - Piper Sandler分析师Peter Keith维持超配评级 目标价从126美元下调至124美元 [9] - UBS分析师Mark Carden维持中性评级 目标价从117美元上调至123美元 [9] - Morgan Stanley分析师Simeon Gutman维持等权重评级 目标价从108美元上调至118美元 [9]

In this Capital Link Trending News Podcast episode, Mr. Hamish Norton, President of Star Bulk Carriers Corp. SBLK, discussed the company's first quarter 2025 earnings, market positioning, and future strategy. Mr. Norton outlined the company's capital allocation strategy and commented on the impact of geopolitical tensions and carbon emission regulations on the dry bulk shipping market.To watch the full conversation, please visit the following link:https://www.youtube.com/watch?v=_GAWmwEOkVIDiscussion Highli ...

公司业绩 - Signet Jewelers Limited将于6月3日周二开盘前公布第一季度财报 [1] - 分析师预计公司季度每股收益为1.04美元，低于去年同期的1.11美元 [1] - 预计季度营收为15.2亿美元，略高于去年同期的15.1亿美元 [1] 历史业绩 - 公司第四季度销售额同比下降5.8%至23.5亿美元，超出分析师预期的23.3亿美元 [2] - 公司股价上周五下跌0.5%，收于66.57美元 [2] 分析师评级 - Telsey Advisory Group分析师Dana Telsey维持"市场表现"评级，目标价62美元 [7] - Wells Fargo分析师Ike Boruchow维持"同等权重"评级，目标价从60美元上调至70美元 [7] - 美国银行证券分析师Lorraine Hutchinson维持"中性"评级，目标价从95美元下调至65美元 [7]

Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36.Also Read: Kidney Disease-Foc ...